Browse News
Filter News
Found 28 articles
-
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors
12/6/2023
Abcuro, Inc. today announced the appointment of Mark Pruzanski, M.D., as Chairman of its Board of Directors.
-
In a deal with Tokyo-based PRISM BioLab, Eli Lilly will gain access to the Japanese biotech’s proprietary platform to develop small molecule inhibitors of protein-protein interactions.
-
Successful drugs from Novo Nordisk and Eli Lilly are just the beginning of what one analyst says could be “the largest therapeutic class of drugs that the biopharma industry has ever seen.”
-
Sales of type 2 diabetes treatment Mounjaro brought in $1.4 billion in the third quarter. However, the company cut its full-year profit guidance due to charges mainly related to recent acquisitions.
-
Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity
11/2/2023
Lilly defines New Products as select products launched since 2022, which currently consist of Jaypirca, Mounjaro and Omvoh.
-
Patients in a late-stage trial treated with Eli Lilly’s GIP and GLP-1 receptor agonist saw a 21.1% mean body weight reduction over 72 weeks following an intensive lifestyle intervention program.
-
Eli Lilly on Tuesday continued its buying spree with a $1.4 billion acquisition of the radiopharma company’s pipeline of clinical and preclinical radioligand therapies.
-
This is the Danish company’s second obesity-focused acquisition in three weeks. Under the deal, Novo Nordisk receives the full rights to develop and commercialize Embark’s lead metabolic platform.
-
Lilly Completes Acquisition of Versanis Bio
8/14/2023
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio.
-
Data from a Phase III study released Tuesday found that Novo Nordisk’s Wegovy lowered the risk of cardiovascular complications and death by 20% versus placebo in overweight and obese adults.
-
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
8/8/2023
Lilly defines New Products as select products launched since 2022, which currently consist of Jaypirca, Mounjaro and Omvoh.
-
Eli Lilly said Friday it plans to pay up to $1.925 billion to acquire Versanis and its lead asset, bimagrumab, a monoclonal antibody that aims to reduce fat mass without affecting muscle mass.
-
This week: Cancer license deals from J&J and BeiGene, a potential $7B acquisition by Roche and confirmed $1.9B Lilly buy, EU fine for Illumina, and more legal challenges to the Inflation Reduction Act
-
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
7/14/2023
Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
-
Versanis Bio to Present New Clinical Data at American Diabetes Association 83rd Scientific Sessions
6/23/2023
Versanis Bio announced an oral presentation at the upcoming American Diabetes Association 83rd Scientific Sessions, held June 23-26, 2023, in San Diego, California, and online.
-
Versanis Bio Announces Completion of Enrollment of the BELIEVE Phase 2b Study in Patients with Obesity
6/21/2023
Versanis Bio ("Versanis"), a clinical-stage biopharmaceutical company advancing novel therapeutics for obesity and other cardiometabolic diseases, today announced that BELIEVE (NCT05616013), a global Phase 2b study in patients with obesity, has completed enrollment, with 507 patients randomized.
-
Legend Biotech Establishes Strategic Advisory Board
4/3/2023
Legend Biotech Corporation announced the formation of a strategic advisory board and the appointments of Michel Vounatsos, former CEO of Biogen Inc., and John Maraganore, PhD, former CEO of Alnylam Pharmaceuticals, as advisors.
-
Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity
1/12/2023
Versanis Bio today announced that the BELIEVE Phase 2b study to assess the safety and efficacy of bimagrumab alone and in combination with semaglutide for the treatment of obesity has begun enrolling at sites in the U.S., Australia, and New Zealand.
-
Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022
11/2/2022
Versanis Bio today shares new preclinical data reaffirming the potential of lead asset bimagrumab as a novel obesity treatment at ObesityWeek 2022, hosted November 1-4 in San Diego.
-
With the appointment of new CEOs, CMOs and CSOs, biopharma and life sciences organizations shuffled their leadership positions as Q3 comes to a close.